Evidence map›Paper›PMID 26876034›Full record

ReviewNature reviews. Microbiology2016

Synthetic biology to access and expand nature's chemical diversity.

Michael J Smanski, Hui Zhou, Jan Claesen, Ben Shen, Michael A Fischbach, Christopher A Voigt

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 1 pooled it
38.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 1 synthesis or guideline pooled it, 473 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Toward development of soil-derivedBiodesign research · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Michael J SmanskiDepartment of Biochemistry, Molecular Biology, and Biophysics and the BioTechnology Institute, University of Minnesota Twin Cities, Saint Paul, Minnesota 55108, USA.
Hui ZhouSynthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Jan ClaesenDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94158, USA.
Ben ShenDepartments of Chemistry and Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA.
Michael A FischbachDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94158, USA.
Christopher A VoigtSynthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Massachusetts Institute of Technology · USUniversity of California, San Francisco · USBiotechnology Institute · USScripps Research Institute · US

Funding

Enediyne Biosynthesis and EngineeringR01CA078747 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEN, BEN · 1999 to 2015
$3.4M
AT-less Type I Polyketide SynthasesR01CA106150 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEN, BEN · 2004 to 2015
$3.3M
Discovery and biosynthesis of diterpenoid natural products in actinomycetalsR01GM114353 · NIGMS · SCRIPPS FLORIDA · PI SHEN, BEN · 2016 to 2019
$1.8M
NCI NIH HHS R01 CA078747NCI NIH HHS R01 CA106150NIGMS NIH HHS R01 GM114353
6 · The paper itself

Abstract

Bacterial genomes encode the biosynthetic potential to produce hundreds of thousands of complex molecules with diverse applications, from medicine to agriculture and materials. Accessing these natural products promises to reinvigorate drug discovery pipelines and provide novel routes to synthesize complex chemicals. The pathways leading to the production of these molecules often comprise dozens of genes spanning large areas of the genome and are controlled by complex regulatory networks with some of the most interesting molecules being produced by non-model organisms. In this Review, we discuss how advances in synthetic biology--including novel DNA construction technologies, the use of genetic parts for the precise control of expression and for synthetic regulatory circuits--and multiplexed genome engineering can be used to optimize the design and synthesis of pathways that produce natural products.

Indexed as

Multigene FamilyBacteriaBiological ProductsDrug DiscoveryGene Expression RegulationMetabolic Networks and PathwaysSignal TransductionSynthetic BiologyBiological Products

Identifiers

PMID26876034
PMCPMC5048682
OpenAlexW2254470084

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.